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O objetivo deste relatório é descrever a minha 
experiência durante o estágio decorrido no INFARMED, 
I.P., no Departamento de Produtos de Saúde no âmbito 
do Mestrado em Biomedicina Farmacêutica.  
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The purpose of this report is to describe my experience in 
internship elapsed at INFARMED, I.P. in the Department 
of Health Products in the scope of the Master's degree in 
Pharmaceutical Medicine. 
The report is divided into an initial part where I make a 
general framework of the medical devices, what they are, 
how they are qualified/classified, how they are currently 
regulated and what is proposed to change. Next, I do a 
description of the tasks I performed and finally a 
discussion of the key points of these tasks. 
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1. Introduction 
This report is performed within the scope of a curricular internship of the Master´s Degree in 
Pharmaceutical Medicine. My internship occurred at Infarmed – National Authority of Medicines 
and Health Products, I.P. from November 2013 to October 2014.  During the first seven months I 
was in the medical devices evaluation department the “Direção de Produtos de Saúde”(DPS) and 
following four months I moved to the medicines evaluation department “Direção de Avaliação de 
Medicamentos” (DAM). The initial program included solely the training in DPS, however during 
the internship there was the opportunity to training also in DAM. The experience passed in DAM 
will not be the focus of this report, so I will just describe my experience in DPS and I will do a 
critical appraisal and specify the principal problems that I found in the different tasks I have been 
assigned.  
I applied to do this internship because I wanted to gain experience in an area different from my 
previous professional experience. The internship in the Competent Authority (CA) was the 
opportunity I was looking for.  
  
1.1. Objectives 
The main goal of this internship was to obtain a global vision of Medical Devices’ regulation and to 
know how the CA supervises the market. For this, the following specific objectives have to be 
achieved: 
- Qualify and classify Medical Devices (MD) 
- Know the current legislation (National and European) and Guidelines applicable to MD  
- Collaborate in the process of the formal conformity assessment of MDs 
- Work with the CA manufacturer’s platform (FABDM) and distributor’s platform (SDIV) 
- Use the tools and mechanisms established under the European cooperation for market 
surveillance: prepare and develop the Compliance and Enforcement Group (COEN) and 
enquiries  
- Know and comply with the quality management system of the institution including the 
manual and Standard Operating Procedures (SOPs). 
Apart these goals specifically related to the MDs environmental the internship was also the 
purpose improve and give new a soft skills as:    
- Communication skills (written and verbal) 
- Time management 
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- Being a team player 
- Organizational skills 
- Sense of responsibility 
- Critical sense  
- Diligence 
1.2. Host Institution 
INFARMED – National Authority of Medicines and Health Products, IP hereafter designated as 
INFARMED is a governmental agency accountable to the Health Ministry. Its purpose is to 
monitor, assess and regulate all activities relating to human medicines and health products for the 
protection of Public Health. So, it is INFARMED´s competence, to license, certify, authorize and 
approve entities, activities and procedures. The mission of this institution is supervising the 
sectors of human medicines and health products and ensuring the access of health professionals 
and citizens to quality drugs and health products, effective and safe. 
INFARMED as stated in activity plan for year 2014 assumes an important role in European and 
International context in addressing emergent challenges as strengthening competitiveness in the 
pharmaceutical sector, fast technological advance, the growing demand in terms of transparency, 
effective combating of falsification and counterfeiting (1). 
INFARMED is divided into several units according to the follow organizational chart: 
 
 
Figure 1 – Organizational chart of structure and organization of INFARMED, IP (2) 
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1.2.1. “Direção de Produtos de Saúde” 
The DPS is one of the basic units of INFARMED that includes the areas of MDs, cosmetics and 
Personal Care Products. Additionally, this department has a subunit of vigilance, the “Unidade de 
Vigilância de Produtos de Saúde”. The DPS has the mission of regulation, market surveillance and 
vigilance of health products encompassing the clinical investigation of MD according to the 
highest standards of protection of public health. DPS participates in the responsibility of ensuring 
that healthcare professionals and citizens in general have access to health products that comply 
with applicable regulatory requirements (2). The DPS consists in a multidisciplinary team 
composed by professionals from various areas of health and technology including pharmacists, 
engineers, veterinaries, biologists and radiographers. Taking into account the great diversity of 
MD products, a multifaceted team like this is undoubtedly of high value for the operation of this 
department. 
 
1.3. State of the art 
 
1.3.1. Medical Devices Market 
The MDs industry is a complex and diverse area considering that the term "medical device" covers 
a vast range of equipment, from syringes and band aids to pacemakers and breast implant. It 
constitutes a key sector for healthcare and it is one of the most innovative sectors, improving and 
saving lives by providing innovative solutions for diagnosis, prevention and treatments (3, 4).  
The social and political changes during the last years namely ageing population, economic global 
recession, increasing of patient expectations about health care and access to innovative products 
are the current issues that MD´s market and Governments have to deal. Due to this crisis, the 
budgets of National Health Systems (NHS) are constrained, threatening the reimbursements and 
reducing the reimbursements’ rates which, ultimately, affect the development and 
competitiveness of the MDs´ Industries. Thus, the Governments and their National Competent 
Authorities (NCA) have to deal with the increasing needs of citizens and, at the same time, with 
the scarce economic resources (3, 5). 
The international regulatory harmonization and its coordination is recognized by all MD´s 
stakeholders as a crucial measure for improving the confidence in the European system not only 
within the European Union (EU) but also outside of it. 
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 The measurement of the value of the MDs through the Health Technology Assessment Systems 
(HTA) is an important tool used by the decision makers to control the scarce resources. However, 
it is important be aware that this tool should not be used only as a way of cost-containment but 
should be used to assess the real value/ effectiveness of the MD in the context of the citizen’s 
needs. It is necessary to create guidelines for good HTA practices, develop standardised practices, 
predictable and common criteria for HTA methods and designed specifically for MDs. Industry 
needs to provide products that increase efficiency and reduce the costs. For instance, MDs that 
facilitate minimally invasive surgery that allow faster recuperation of patients and also increase 
the number of operations performed per day of surgery (6). 
 
1.3.2. Medical Devices Regulatory Environment 
Taking into account that my internship was performed in the Portuguese CA, in this report I will 
refer only to the law applicable in the EU. 
The MD regulation began in the United States of America, the US Medical Device Amendments, in 
1976 under the responsibility of the Food and Drugs Administration. After this, MDs were defined 
and the risk-based classification was introduced and the regulatory process for each class was 
outlined. In Europe, the first MDs regulation was outlined only in the '90s, with the introduction 
of one of the most important directives, the Directive 93/42/EEC (7).  
The regulatory framework for the MDs in European Union is based on three directives: 
 
- Directive 90/385/EEC – Active Implantable Medical Devices Directive (AIMDD) 
- Directive 93/42/EEC - Medical Devices Directive (MDD) 
- Directive 98/79/EC – In Vitro Diagnostic Directive (IVDD) 
 
All these directives are based on the "New Approach" and aim to ensure the functioning of the 
internal market as well as a high level of protection to human health and its safety. The “new 
approach” means that the legislation specifies only the essential requirements that are general 
and mandatory and the detailed technical specifications used to demonstrate conformity with the 
essential requirements are according to the voluntary harmonized standards (8, 9). MDs are not 
subject to a pre-market authorisation by a regulatory authority but only to a conformity 
assessment which, for medium and high risk devices, involves an independent third party, a so-
called "Notified Body" (NB). Once certified, devices bear the CE marking which allows them to 
circulate freely in the EU/EFTA countries and Turkey. 
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These directives have been reviewed and updated over time by the introduction of several 
directives, including the last technical revision triggered by Directive 2007/47/EC amending the 
AIMDD and MDD. This directive also amends Directive 98/8/EC which concerns the placing of 
biocidal products on the market (10). 
  
According to the MDD, all MDs have to fulfill with the essential requirements stated in this 
directive before being placed on the market. These requirements cover the MDs themselves and 
the materials they are made of and the tests they must pass, including standards on clinical 
investigations. The compliance with these essential requirements serves as a mechanism for proof 
that the MD complies with its intended purpose and it is safe. The European NCAs rely upon the 
fulfillment of these requirements to certify the formal compliance of devices placed on the 
market (9, 11, 12). 
 
1.3.3. Classification of MD 
To classify MDs, it is necessary to be aware that it is framed in the definition of MD. According to 
the MDD, a MD is any instrument, apparatus, appliance, software, material or other article, 
whether used alone or in combination, including the software intended by its manufacturer to be 
used specifically for diagnostic and/or therapeutic purposes and necessary for its proper 
application, intended by the manufacturer to be used for human beings for the purpose of:  
- diagnosis, prevention, monitoring, treatment or alleviation of disease,   
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, 
- investigation, replacement or modification of the anatomy or of a physiological process, 
- control of conception, 
- and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function by 
such means (13).  
 
The classification of MDs is a ‘risk based’ system that evaluates the potential risks associated to 
the devices and the vulnerability of human body. They are classified according to a graduated 
system. It means that in this system the level of control corresponds to the potential danger 
related to the type of the MD concerned. MDs are classified into classes: I, IIa, IIb and III. The 
conformity assessment process is also performed according to MDs classification. Thus a class III 
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MD will have to conform to more rules to prove its effectiveness and harmlessness than an 
inferior class device. 
The classification of MDs is determined according to the duration of use (transient, short term, 
long term), contact with the body (brain, heart, etc.), degree of invasiveness and the potential 
risks associated with design and manufacture. The classification rules are described in Annex IX of 
Directive 93/42/EEC and in MEDDEV 2.4/1 Classification of MD. There are eighteen rules and they 
are subdivided into four groups (Table 1) (14). 
 
Table 1 – Classification Rules-MD (14) 
 
 
 
 
 
 
 
 
An active medical device is a device that for its functioning needs on a source of electrical energy 
or any source of power other than that directly generated by the human body or gravity (13). 
 
The in Vitro Diagnostic Medical Devices (IVDs) is a device, whether used alone or in combination, 
intended by the manufacturer for the in vitro examination of specimens derived from the human 
body solely or principally to provide information for diagnostic, monitoring or compatibility 
purposes. This includes reagents, calibrators, control materials, specimen receptacles, software, 
and related instruments or apparatus or other articles (15). Similarly to the other MDs, these are 
classified into four groups, two classes annex II (list A for high-risk devices and list B for medium-
risk devices), a self-testing IVD class for devices intended for use directly by lay individuals and a 
general class with the lower risk (Table 2) (16).  
  
Rules Device 
Rules 1 – 4 Non-invasive Devices 
Rules 5 – 8 Invasive Devices 
Rules 9 – 12 Active Devices 
Rules 13 –18 Special rules 
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Table 2- IVDs’ Classes (16) 
 
 
1.3.4. CE Marking 
CE marking is the MD manufacturer´s claim that a product meets the essential requirements of 
European Directives and is a legal requirement to place a device in the EU market. It shows that 
the device is fit for its intended purpose and meets legislation relating to safety (Figure 2).  
 
 
Figure 2– General order of activities in compliance with European regulation (17, 18) 
 
Additional to the CE marking, the manufacture or its authorized representative (i.e)   within the 
European Economic Area (EEA) must sign a Declaration of Conformity (DoC) (Figure 3). The 
manufacture is the natural or legal person with responsibility for the design, manufacture, 
packaging and labelling of a device before it is placed on the market under his own name, 
regardless of whether these operations are carried out by that person himself or on his behalf by 
a third party and the authorized representative is the person established in the Community who, 
Class Examples 
Annex II, list A reagents including related calibrators and controls for use 
in HIV, HTLV and hepatitis assays 
Annex II, list B reagents including related calibrators and controls for use 
in rubella, toxoplasma, cytomegalovirus and chlamydia 
assays. 
Self-test test kits used in a home environment – pregnancy testing. 
General bacteriological culture media, cell cultures for virus 
isolation, specimen containers. 
AIMDD 
90/385/EEC 
MDD 93/42/EEC 
IVDD 98/79/EC 
Annex I 
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explicitly designated by the manufacturer, acts and may be addressed by authorities and bodies in 
the Community instead of the manufacturer [13]. This document also indicates that the product 
meets all the necessary requirements laid down in the applicable directives (1, 11, 15).   
 
Figure 3 – Example of Declaration of Conformity (19) 
 
For all devices except Class I non-sterile and non-measuring, the manufacturer should also have a 
Quality Assurance System (QAS) that ensures that MD fully meets the standards defined in the 
technical documents. The procedures related to this quality assurance are set out in Annex II (full 
quality assurance) and Annex V (production quality assurance) of MDD. In the technical dossier, 
the manufacturer displays all data that prove compliance with these requirements including the 
clinical evaluation and risk assessment. For all classes of devices above class I (including class I 
sterile or class I with measure functions), the QAS and technical dossier must be audited by a NB, 
a third party designated by CA to audit MD companies and products.  Specifically, for these types 
of MDs, it is required a CE Marking Certificate for the MD issued by NB. 
  
 
 Manufecturer Identification 
Product identification and 
Applicable directives 
 
Standards 
Responsible person 
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1.3.5. Notified Bodies 
The NBs are third party bodies designated/accredited by CAs to carry out conformity assessments 
of MDs under the MDs Directives. The assessment usually includes an audit of the manufactures' 
quality systems and an evaluation of the MD’s technical documentation depending on their 
classification. The manufacturers should choose the NB taking into account their technical 
competencies and experience. 
A list of designated NBs from each Member State per directive and per scope of action is available 
in Nando’s database in the European Commission website (20). 
Decisions taken by the NBs in accordance with Annexes II, III, V or VII of MDD shall be valid for a 
maximum of five years and may be extended on application, made at a time agreed in the 
contract signed by both Parties, for further periods of a maximum length of five years (21). 
The NB issues a CE Certificate which certifies that the product(s) is (are) covered in scope Figure 4. 
 
 
 
 
Figure 4 – Certificate–Example of EC (22) 
 
 
 
Certificate number 
Manufacturer 
Products / Device(s) Category 
Expiry date 
NB number 
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1.3.6. Portuguese Legislation 
In Portugal, MDs are regulated by Decree-Law 145/2009 of the 17th of June that transposes the 
Directive 2007/47/EC into the national law. It establishes the rules regarding investigation, 
manufacturing, commercialisation, functioning, supervision and advertising of MDs (including 
active implantable) and respective accessories. Regarding to the IVDs, the Directive 98/79/EC is 
transposed to the Portuguese law under Decree-Law no. 189/2000 of 12th August (15, 16).  
 
1.3.7. Harmonized and Standards Guidance 
The European Harmonized Standards under the EU harmonization legislation are published in the 
EU Official Journal. These publications are listed harmonized standards that are in place and 
should be applied for each MD in accordance with the applicable directives (23).The harmonized 
standards give the presumption of conformity with the Essential Requirements of the applicable 
directive. The use of the standards is not mandatory. However, if not harmonized standards are 
used, the manufacturer has to document the alternative solution adopted to fulfill the essential 
requirements of the directive (8). 
Besides the directives, there are also non-binding Guidance documents like MEDDEVs, consensus 
statements and interpretative documents that ensure uniform application of the relevant 
provisions of the directives within the EU. 
MEDDEVs have the objective of put forward a common approach by MDs manufacturers and NBs 
involved in the conformity assessment procedures, and by CAs charged with safeguarding Public 
Health. These guidelines are the result of a consultation process with all the stakeholders, and 
result from the reflected positions of representatives of CAs and Commission Services, NBs, 
industry and other interested parties in the MDs sector (24). 
 
1.3.8. New European regulatory proposals 
The current MDs and IDVs are increasingly sophisticated and innovative but the current legislation 
has not kept pace with technical and scientific progress. The great diversity and innovation 
capacity in this sector has been a challenge to the regulation of these innovative products, 
specifically by seeking clinical evidence that support their safety and performance. Hence, 
European Commission adopted in 2012 a package on innovation in health, consisting of adapting 
the MD legislation to the needs of tomorrow with the aim of achieving a suitable, robust, 
transparent and sustainable regulatory framework. 
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The new regulatory framework of MDs proposed by European Commission consists of two 
proposals for regulations, one is applicable to IVDs and another is applicable to the other MDs 
(including the implantable active medical devices).  
Major goals of these regulation revisions include improving harmonization between Member 
States (since the application of the existing MDs directives is different across the EU) and 
reinforcing the safety and health of patients, while still ensuring prompt access to innovative 
devices for patients and medical professionals.   
The main elements of the proposal regulations are: 
- The directives will be replaced by regulations. So they will have direct effect in Member 
States allowing for a better harmonization in the European market; 
- Cover legislation gaps. Currently there are regulatory gaps or uncertainties with regard to 
certain products such as implants for aesthetic purposes; 
- Determine specific requirements for the NBs’ designation and create mandatory 
accreditation standards; 
- Develop specific measures for controlling and monitoring the activities performed by NBs.   
- NBs shall conduct unannounced audits of manufacturers to evaluate their compliance 
with the legal obligations; 
- Clarify the rights and responsibilities of all market players of MDs including the 
manufacturers, importers and distributors; 
- Create a public database of MDs at European level accessible to all, including not only 
health care professionals but also patients; 
- Adapt the rules to technological and scientific progress, for example, adapt the 
requirements of safety and performance to new health technologies, such as software or 
nonmaterial used in health care; 
- The creation of a new expert group (the Medical Device Coordination Group). It will have 
the power to review and comment on NB assessments of high-risk MDs before the MD is 
put on the market. 
- Create a unique identification system for MDs that ensures their traceability throughout 
all the distribution chain; 
- Introduction of the new concept of "qualified person". A person responsible for 
regulatory compliance; 
- New rules for the reprocessing of single-use MDs if the reprocessors take on the 
responsibilities of the manufacturer; 
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- Establish new requirements for clinical trials to ensure safety of patients and users; 
- Provide better coordination between NCA to ensure that only the safe MDs are available 
on the European market (16, 25). 
2. On- the-Job Training 
During my internship at DPS I had the opportunity to perform tasks of technical of market 
surveillance, more specifically directed to the market of the Portuguese manufacturers. I 
collaborated in the validation/evaluation processes of MDs registered in an online platform 
directed to manufacturers/authorized representatives, named FABDM. In addition, I did the 
issuance of certificates of free sale, evaluated MDs as part of a campaign, replied to requests for 
information and collaborated in the development of a COEN. 
Along this period I also had the opportunity to contact with other areas, including quality and 
surveillance of MDs. However, I did not work directly in these areas, so I will later only make a 
brief reference to them. 
In compliance with INFARMED’s quality policy and to comply with the quality system, I was 
instructed to follow the established procedures and comply with the quality manual. Additionally I 
had the chance to attend an internal audit that gave me a more accurate view of the quality 
management system. 
 
2.1. Information requests 
During the first weeks, and after being aware of the principal MDs' legislation and guidelines, I 
began to reply to information requests received by DPS via email. The majority of the requests 
were related to the MDs' regulatory framework including their qualification and classification. I 
also requested to duties of manufacturers/ authorised representatives and distributors in the 
registry of MDs and patient/ heath care professionals’ doubts and concerns about the MDs. 
The replies to questions about qualification and classification usually included the definition of 
MD according to the Directive 93/42/EEC and the reference to the guideline MEDDEV 2.4 – 
Classification of MDs. 
In case of requests related to the registry of distributors and manufacturers/authorized 
representatives, the companies were informed that according to Decree-Law 145/2009 of the 
17th of June that transposes to our national law the Council Directive 93/42/EEC of 14th of 
June, who places the MDs on Portuguese market, must notify INFARMED. 
While manufacturer, when MDs of class IIa, IIb and III and implantable active MDs, are placed on 
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the Portuguese market, the manufacturer or the authorized representative needs to notify them 
in INFARMED, according to the Article 11 of the Decree-Law 145/2009 of the 17th of June that 
transposes Article 14 of Council Directive 93/42/EEC of 14th of June. For class I MD, systems and 
sets (i.e. particular medical procedures consisting of various medical devices that are packed and 
dispensed jointly as a single unit, and are placed on the market under a single trade name [26]) 
and custom made MD, national manufacturers or his authorized representative based in Portugal 
shall do their registry. The notification must be carried out in the online notification system for 
the manufacturers available in INFARMED’s website. 
On the other hand the distributor of the MDs in Portugal (class I, IIa, IIb, III and implantable active 
medical devices),must carry out the notification of the devices as well, according to the Article 41 
of the above mentioned Decree-Law in the online notification system for distributors. The 
distributor registry is a legal obligation specifically required by the Portuguese Legislation. The 
MDD does not address this registry. However, Portugal adopted this system in order to have a 
better knowledge of the MDs market in our territory. 
The registers performed by the manufacturer and the distributor are independent of each other 
and they are updated in two different databases. 
 
In order to reply patients’ requests regarding the safety and conformity of the MDs, I checked if 
the MD was registered on FABDM or SDIV. If the register was not performed, it was necessary to 
contact the distributor or the manufacturer in order to apply for registration and then proceed to 
the formal evaluation of the MD. After this, and according to each specific situation, it was 
possible to reply to the patients.   
 
2.2. DMs’ Evaluation 
As previously referred, MDs need to bear a CE mark to be placed in the market. The exceptions 
are the custom-made devices (i.e. a MD specifically made in accordance with a duly qualified 
medical practitioner’s written prescription which gives, under his responsibility, specific design 
characteristics and is intended for the sole use of a particular patient [26]) and devices intended 
for clinical investigation that need to comply with the provisions of Annex VIII of MDD regarding 
the statement on devices for special purposes (27). 
 
For class I devices, the manufacturer/ authorised representative is the only responsible for placing 
the CE mark. He shall elaborate the declaration of conformity and notify the CA. 
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For classes IIa, IIb, III, in the case of products placed on the market in a sterile condition and with a 
measuring function it is necessary the intervention of NB. In this case, it is the NB that issues a 
certificate of conformity according to the conformity assessment procedure chosen by the 
manufacturer.   
 
Table 3 –Conformity assessment procedures (14) 
 
 
 
2.2.1. MD’s evaluation- FABDM’s platform 
 
INFARMED uses the FABDM platform to perform the formal MDs’ evaluation. Following the 
implementation of the Medical Device Repository, it was considered appropriate to develop a 
database that allows the MD's registry as per the applicable legislation. So, in 2012 the on-line 
registration for MDs/IVDs by its Manufacturers/Authorized Representatives (FABDM) was 
Classes  Evaluation procedures- Annexes 
Class I VII 
Class I sterile and with measuring function 
medical devices   
VII + IV, or V, or VI 
or 
II (excluding section 4) 
Class IIa VII + IV, or V, or VI 
or 
II ( excluding  section 4) 
Class IIb III + IV, or V, or VI 
or 
II ( excluding  section 4) 
Class III III + IV, or V 
or  
II (including section 4) 
Implantable active medical devices XII + XIII or XIV 
or 
XI 
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launched and came to replace the previous registration procedures. This platform allows 
consulting the conformity documentation attached and sending the requests of elements directly 
to the manufacturer. 
In the FABDM, the register of Class I MDs, Class I sterile and MDs with measuring function, DIVs, 
MD systems and sets generates a task of the respective MD automatically.  However, for Class IIa, 
Class IIb, Class III and Implantable active MDs the tasks are not generated automatically, they are 
created by own manager.  This type of evaluation is named ad-hoc evaluation and usually it 
appears in the context of other procedures / surveillance actions, such as certificate requests.  
I performed the evaluation of different types of MDs through the FABDM platform as process 
manager. The medical device systems and sets (MDSS) for collecting stem cells during delivery 
and sets for first aids were the first type of processes that I managed. The evaluation of these 
MDSS presupposes the individual evaluation of the MDs that are part of the set. This includes the 
evaluation of labeling and instructions for use. In MDDS, the CE marking is not affixed to the 
packaging of the set but is affixed individually to each device. Additionally, during the evaluation, 
it is necessary to check the data inserted in the platform such as manufacturer's data, MD’s name, 
MD’s reference, NB and Global Medical Device Nomenclature (GMDN is an international system 
of terms applied to MD for their identification) code and the description and intended purpose of 
the MD. In case that supplementary information is required, an element request was sent directly 
to the MD’s responsible. After collecting the required information, the final evaluation by process 
manager is performed and then a message is generated for the final approval by the technical 
direction. The MD's status is updated after superior approval (validated) (28). 
After finishing the evaluation of the MDSS, I started the evaluation of the MDs of class I and II, 
more specifically, MDs of the type of bandages, compresses, and chirurgical instruments. The 
major difference between the formal evaluation of class I and class II  devices is the fact that the 
essential requirements of class I MDs need to be analyzed and for Class II it is not necessary 
because class II MDs are already evaluated by NBs. The analysis of the essential requirements 
includes the confirmation of adequacy of the standards and specifications used by manufacturer 
to the type of MDs and if they are the most current ones. There are thirteen essential 
requirements subdivided into several points and described in the annex I of MDD. Manufacturers 
need to specifically refer to each requirement are applying and indicate their applicability or not. 
Whenever applicable, they have to refer which standard or procedure was used to ensure 
compliance with this requirement (16). The standards that cover the essential requirements of 
the MDD are published in the Official Journal of the European Community (29).  
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The evaluation of the label and user instructions is made according to the set out in the MDD and 
in the MDs’ Portuguese law. Furthermore, the manufacturers upload the CE certificate and the 
DoC in the field “associated documentation” and they must also be analyzed during the MD 
evaluation. 
  
2.2.2. SDIV’s platform 
As mentioned above, the Decree-Law 145/2009 of the 17th of June and Decree-Law 189/2000 of 
the 12twof August determine the obligation of distributor to registry the MD placed on the 
market. This allows the INFARMED to gain knowledge about the MDs placed in the market and 
the economic agents involved in the supply chain. 
In this platform, the distributor must include mandatory information as the complete 
identification of Manufacturer/ Authorized Representative, a detailed product description, 
designation of the product,  GMDN code or, alternatively, a brief description of the MD and the 
purpose of its use, brand and model, class of risk, and NB’s code (if applicable). 
Validation of the information contained in the register is triggered by different processes, in a 
proactive way when the procedures are carried out in the context of campaigns or within the 
context of the codification. Alternatively, validation may be triggered in a reactive way when the 
certificate was requested to attest the registration of the products or any other surveillance 
action of MD’s market.  
My experience with SDIV boils down to specific situations concerning requests for information 
and within the campaign I attended (30). 
 
2.3. Campaigns 
Campaign process is a mechanism by which the DPS and the Directions of Proof of Quality and/or 
Licensing and Inspection perform an action to a specific group of DMs. The DPS collaborates in the 
campaigns by performing the documental evaluation and verifying the compliance with the 
essential requirements according to the MD´s legislation. 
Within this type of processes I performed the evaluation of the labels and instructions for use of 
MDs' disinfectants. Commonly, disinfectants are classified according to rule number 15 of the 
MD’s classification. Disinfectants intended to be used for disinfecting MDs are classified, in 
general, as Class IIa, unless they are specifically designed to disinfect invasive MDs. In this case 
they are classified as Class IIb.  Once these devices are classified as Class IIa or Class IIb, a NB is 
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required to assess the technical documentation. Due to this, during the evaluation process of 
labeling, it is of major importance to check if the CE mark includes a NB’s number (Figure 5) (21). 
 
 
 
 
 
 
Figure 5 – Shown is the CE mark and NB’s number (31) 
 
To perform the assessment of these MDs, I also used to verify if the symbols affixed were 
according to the standard ISO 15223-1:2012 (32). 
 
2.4. Compliance and Enforcement Group (COEN) and Enquiry CA related to regulatory 
status and questions of classification. 
Throughout the MDs' evaluation, some doubts/questions about regulatory issues such as 
qualification and classification or even non-compliances may appear. Hence, in some cases it is 
necessary to contact other CAs to clarify these issues. In case that the issue is specific to a 
DM/manufacturer, it is triggered a COEN. The COEN is a process developed at European level that 
allows the CAs to contact manufacturers responsible for DMs in European Community in a faster 
and more objective way. For this purpose, it is used a common document named COEN2 that 
harmonises the communications between the CAs requiring their cooperation on the market 
surveillance (33). 
The Enquiry to MD CAs is another request used by CAs to determine borderline or classification 
issues. The applicant sends to other CAs a form that should include a summary (description of the 
problem), the question and all pertinent information (e.g. the scientific references and 
guidelines). The answer may be positive, negative or new proposal. The CAs shall respond 
providing a rationale with their opinion. The final assessment is carried out in the working party 
on borderline and classification after establishing a proposal text to be included in the manual on 
borderline and classification.  
During my internship I only had the opportunity to help to prepare a COEN concerning to custom-
made MD. I did not prepare any Enquiry to MD CA but I had the opportunity to see several ones.  
  
xxxx 
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2.5. Certificate of Free Sale (CFS) for Medical Devices and Certificate Manufacturer / 
Distributor 
For products that are exported outside of the EEA, the CAs of the receptor countries that 
recognize the European Legislation request a proof of compliance with the current legislation of 
the origin Country. The main purpose of the CFS is the liberation of the products when exported 
for third countries.  Usually, the certificates are valid for one year, but in exceptional duly justified 
cases it can go up to 3 years validity.  
In order to give a certificate, it is necessary that the applicant: 1) is  registered as manufacturer at 
INFARMED; 2) has all the fees paid; and 3) the device(s) in question must be validated (meeting all 
compliance requirements stated in MDD)(34).  
The Certificate Manufacturer/Distributor certifies that the manufacturer or distributor, 
respectively, comply with the registration requirement of MDs (according to the Article 11 for 
manufacturers and article 41 for distributors of the Decree-Law 145/2009 of the 17th of June) and 
the information provided in the context of MDs’ registers  is validated by INFARMED (35). 
Along the internship I performed one CFS. In such case, I had to do a previous validation of the 
MD because it was registered but not validated yet.  
 
2.6. Medical Devices Vigilance 
Although I did not perform vigilance tasks as part of the DPS, I contacted with this area and I 
learnt some fundamental concepts.  
Post-market surveillance and vigilance is a legal obligation of the manufacturer as established in 
MD legislation to ensure the continued safety and performance of devices in use. It is also 
important to minimize the risks in warning situations through effective communication and recall 
of products if necessary. 
INFARMED is the responsible for the National Vigilance System of MD, that aims to collect 
information concerning MD use and do their evaluation and, ultimately, take appropriate 
measures to ensure the safety and welfare of citizens, if necessary (36). 
The manufacturers, authorized representatives, distributors, health care professionals and other 
MD’s stakeholders, as stated in article 27 of the Decree-Law 145/2009 of the 17th of June, should 
communicate to the CA all incidents that occur in Portugal. The report should be made by 
completing the respective form available in INFARMED website and send it by email to the 
Vigilance Unit of health products (37). 
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3. Discussion 
Many of the requests for information that I answered were related to the issues of classification / 
qualification of DMs. Although the existing rules adequately classify the vast majority of existing 
devices, the classification of a small number of products is not so straightforward. Such cases 
include those devices that are borderline cases between two different classes of MDs. In these 
particular cases the risk classification may be not adequate to these MDs and these situations 
could result in a wrong level of conformity assessment in the light of the hazard represented by 
the device (38). Furthermore, in my opinion the issues of classification/qualification arise also due 
to the difficult interpretation of the legislation. 
Specifically, two of the total requests for information that I had in my charge were borderline 
cases. One was about eye drops and the other was about insect repellent. Several of eyes’ drops 
are qualified as MDs but this qualification is not always consensual, and so in the borderline 
manual this issue is already included. The problem with the qualification of this eye drop is the 
intended purpose and its mode of action. The manufacturer classified its product as Class II for 
treatment of dry eye or ocular discomfort including contact lens wearers. As the manufacturer 
does not exclude non users of contact lenses, the purpose of this eye drop is not specifically 
hydrating of the contact lenses. So, the issue about the correct qualification of this product is 
raised and the rule 15 of Annex IX of MDD is excluded. Besides this, the manufacturer indicates an 
anti-inflammatory action that raises another issue: the mode of action. Eye drops whose principal 
mode of action is pharmacological, immunological or metabolic will fall under the definition of a 
medicinal product. In order to clarify these issues I asked for some clarifications, however I don´t 
know the conclusion of this process because when I finished my internship the process was still 
ongoing. Nevertheless, I think that after clarifying the mode of action, the product may be 
classified as class IIa or class IIb, in accordance with classification rule 5  or qualified as  medicinal 
product (14, 27, 39).  
Through an information request, I received another borderline case about insect repellent. In this 
case, the manufacturer asked directly how he could qualify the product. He specified that his 
product was a repellent bracelet against malaria-bearing mosquitoes to prevent malaria. At a first 
instance, it seems that this product fits with one of DM's purpose according to MDD, "prevention 
of disease", but it is not true. Actually the primary purpose of this product is repelling Anopheles 
mosquitoes and their bites. So, according to Annex V of Directive 98/8/EC, this product is 
considered a biocide (39, 40).   
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During the evaluation of the disinfectants, in the framework of the campaign, the borderline 
qualification was again raised. Usually the common disinfectants for disinfection of various 
surfaces as floors and sanitary facilities are regulated within the biocides legal framework.  
According to the purpose for use, disinfectants may be regulated as MDs, medicines or biocides. 
In some of the labels of the disinfectants that I evaluated, it is stated that the product is for 
multiple purposes including disinfection of surfaces, walls, countertops and also for surgical 
instruments. In these cases, these products should not be covered by MDD, however the 
manufacturers include them within this directive. Only disinfectants whose main purpose is 
disinfection of MDs can be qualified as MDs (39, 41). Moreover, some of these disinfectants had 
faults/defaults in their labels and instructions for use. More commonly, labels and instructions for 
use are not translated to Portuguese, it is used outdated symbols and even the instructions for 
use are absent. All of these issues were collected and recorded to take the suitable measures in 
the course of the campaign. 
Besides these specific cases, many other issues/doubts on MDs’ qualification and classification 
occur very often. For instance, similar products that are intended to be ingested can be qualified 
as medicine, MD or food supplement. This issue needs to be clarified for keeping the safety of the 
patient and have a consistent rule across the EU.  The issue about classification/qualification is 
already provided in new proposed Regulations on MDs and on IVDs.  
In general, the principal problems I found during the evaluation of MDs were: 
- Error in the GMDN code or outdated code 
- Lack of t instructions for use or labeling  
- Non-compliant labeling 
- The labeling and/or instructions for use are not in national language (Portuguese)  
- MDs without DoC and/or EC Certificate 
- Outdated standards 
- Lack of clinical evaluation 
Most of these problems are solved easily with an order of elements such as the correction of the 
GMDN and updating of the standards. Regarding to labeling and instructions for use, the main 
problems detected were symbols that were not in accordance with ISO standard 15223-1: 2012 
and the absence of mandatory elements such as address of the manufacturer, storage conditions 
and indication of instruction for use. Often the manufacturers justify the lack of information as a 
consequence of the insufficient space in labeling. Another common problem is the labeling and 
instructions for use that are not presented in Portuguese. Many Portuguese distributors complain 
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to the difficulty in obtaining labels and the instructions for use in Portuguese by manufacturers. 
As the MDs market for Portugal is small the abroad manufacturers do not want to make large 
investments including performing the translations. 
Another issue that sometimes happens is the absence of clinical evaluation data. This is because 
many of the Portuguese manufacturers are manufactures of the simpler devices of low classes. In 
most cases, this issue is solved by the fact that the products are in the market for several years 
(well established use) and, thus, are able to make an assessment based on the review and 
compilation of published clinical experience.  Nevertheless, often, manufacturers have difficulties 
in finding scientific literature of MDs that are equivalent to their devices. 
Generally and given the current paradigm of the market for MDs and following the scandal with 
“Poly Implant Prothèse” (PIP) it is clear the need to implement the planned measures foreseen in 
new regulation proposal. The EC and EU countries have taken joint action to increase control of 
the MDs based on current legislation, the so-called PIP Action Plan. The principal areas of action 
of this plan are: functioning of NB, market surveillance, coordination between Member states in 
fields of vigilance, communication and transparency. 
The goal of the new Regulations is a tightening up of the regulatory framework, maintaining the 
CE mark system and not performing a complete revision. It is necessary to ensure quality, public 
safety and financial sustainability while it is guaranteed the access to innovative medical 
technology. For manufacturers, the new regulation will impose some additional burdens mainly 
for the small and medium-size enterprises (25).  Hence, for manufacturers, particularly for 
Portuguese manufacturers, these measures will require a greater effort of adaptation, more 
resources and investment. It is also my opinion that this new proposal is essential to ensure the 
high level of safety patient and health professionals and restore their confidence in the MDs and 
simultaneously keep MDs' European competitiveness in the global context. Nevertheless, I believe 
that many of these measures will be a new handicap to the manufacturers in particular for 
Portuguese manufacturers that are typically small enterprises. On the other hand, it is created the 
perfect time for the modernization of these enterprises. One should bet on the integration of 
knowledge coming from the academies, investing more in research applicable to the industry 
context (42). 
Given the current technological and scientific development, not only companies need to help and 
cooperate with the academies but also the other stakeholders, such as the CAs and NBs need the 
cooperation of experts in different areas of technological development. According to this, the new 
proposal also establishes the existence of an expert group to advise and provide assistance (43). 
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In Portugal, in line with some of the proposed measures to the new regulatory framework, 
besides the mandatory registration for manufacturers, distributors also have an obligation to 
register MDs distributed by them. This measure is often contested by distributors because in their 
opinion the register by all distributors is an unnecessary obligation when one of them did a 
previous register of the same MD. Nonetheless, the goal of this measure is to allow for a greater 
control and traceability of MDs that are in the Portuguese market and know all the economic 
operators associated to a specific MD. This matter would be overcome if the registration of MDs 
would be single and centralized (43). The assessment of the MD would be carried out by a 
reference member state just like in the evaluation of medicinal products in the process of mutual 
recognition or decentralized procedures. The evaluation of each MD would be done once in a 
single moment and would be valid for other member states. This would decrease the 
administrative burden of the member states and manufacturers / distributors / importers of MDs 
would only have to notify their products once they were in the European market. By examining 
the distribution platform SDIV and comparing it with the register performed in manufacturer 
platform FABDM, we can see that many foreign manufacturers have their products in the 
Portuguese market but it is not registered in FABDM. With the single register this infringement 
would cease to exist. This issue will be solved with the future Eudamed. It is a database in which it 
will be expected a single record by the manufacturer, distributor and importer valid throughout 
Europe. Besides the MDs’ identification and the economic operators’ identification, the Eudamed 
III will include certificates, vigilance information, clinical investigation and market surveillance (44, 
45). 
Portugal also developed a system for recording and coding devices that allows the tracking and 
identification of the devices used in public hospitals. The encoding process is intended to allow 
characterizing the national market in terms of volume of use and expense value. This is a step 
towards the need to create a unique device identification system for MDs as included in the new 
proposal. The encoding should be in a worldwide level to ensure the proper traceability of the 
MDs (10, 43). 
Despite the fears and uncertainties of the new proposal, it is obvious to all stakeholders that the 
new proposal must be implemented. Until then, it is predictable that many changes and 
corrections will occur, since the new legislative framework is still under construction. Along with 
that, MD companies and regulators have to adapt to meet these new measures. 
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4. Conclusion 
The opportunity to do the internship at INFARMED surpassed the expectations that I had. This 
experience was the catapult that I needed to move to a new area of work and achieve my 
professional goals. Despite being a curricular internship, this was not my first professional 
experience. Previously, I had worked as a pharmacist for four years in a community pharmacy. I 
had the urge to communicate with customers and sense of responsibility. However, I felt like a 
rookie because I found myself in an area that I was totally unaware: MDs and regulation. Although 
I had worked in a pharmacy and I had contacted and sold MDs, I did not know much about this 
subject. The first concepts about MDs were given to me during the Master’s Degree in 
Pharmaceutical Medicine. 
I consider that the main transversal skills that I acquired during the internship were the 
interpretation of regulatory documents and the formal communication in the professional 
context. Moreover today I consider fruitful to have the regulator-side vision. 
The major goals proposed for the internship were achieved. However I would like to have had 
more contact with the Vigilance Unit because I have interests in this area and in my current work I 
need to deal with MDs’ vigilance. Therefore, this experience would have been an added value for 
my professional needs. 
As a pharmacist I was curious to know another department that works with medicines. So, the 
opportunity to pass through the DAM and contact with a different but complementary area was 
grateful and a privilege. 
I believe that the traineeship is of utmost importance to the integration and consolidation of the 
theoretical knowledge acquired during the Masters.  On the other hand, the knowledge acquired 
during the Master's program gave me the skills to successfully finish the training. 
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